Envista (NYSE:NVST) Price Target Raised to $21.00 at Morgan Stanley

Envista (NYSE:NVST) had its target price raised by equities researchers at Morgan Stanley from $19.00 to $21.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price target suggests a potential downside of 22.40% from the company’s current price.

NVST has been the topic of a number of other reports. UBS Group increased their price target on Envista from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 3rd. Leerink Partners set a $35.00 target price on Envista and gave the stock an “outperform” rating in a report on Friday, February 6th. Citigroup began coverage on Envista in a report on Wednesday, April 15th. They set a “neutral” rating and a $29.00 target price on the stock. Piper Sandler reiterated a “neutral” rating and set a $25.00 target price (up from $21.00) on shares of Envista in a report on Friday, February 6th. Finally, William Blair raised shares of Envista from a “hold” rating to an “outperform” rating in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Envista has a consensus rating of “Hold” and an average price target of $27.85.

Envista Trading Down 0.3%

Shares of NVST opened at $27.06 on Friday. The stock’s 50-day moving average price is $26.95 and its 200 day moving average price is $23.65. The company has a quick ratio of 2.04, a current ratio of 2.38 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of 96.65, a P/E/G ratio of 1.85 and a beta of 0.98. Envista has a 12-month low of $15.49 and a 12-month high of $30.42.

Envista (NYSE:NVST) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.Envista’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, research analysts predict that Envista will post 1.4 earnings per share for the current year.

Insider Transactions at Envista

In other Envista news, SVP Mischa Reis sold 9,675 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the sale, the senior vice president owned 32,382 shares in the company, valued at $971,460. This represents a 23.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.99% of the stock is owned by corporate insiders.

Institutional Trading of Envista

Several institutional investors and hedge funds have recently bought and sold shares of NVST. Millennium Management LLC raised its stake in Envista by 1,442.7% in the fourth quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock valued at $52,552,000 after buying an additional 2,263,712 shares during the period. Holocene Advisors LP bought a new stake in Envista in the second quarter valued at approximately $43,936,000. Norges Bank bought a new position in Envista in the 4th quarter valued at about $45,113,000. Alliancebernstein L.P. raised its holdings in Envista by 34.0% in the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after acquiring an additional 1,547,656 shares during the period. Finally, Freestone Grove Partners LP bought a new position in Envista in the 4th quarter valued at about $29,046,000.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.